Catalog No.
RAC09602
Species reactivity
Biosimilar
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Receptor tyrosine-protein kinase erbB-2, 2.7.10.1, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
CAS: 180288-69-1
Applications
Blocking, ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA2113
Assessment of the Effects of Single-Domain Anti-Idiotypic Distribution Enhancers on the Disposition of Trastuzumab and on the Efficacy of a PE24-Trastuzumab Immunotoxin., PMID:40361392
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index., PMID:40149365
Development of a mertansine-specific DNA aptamer and novel high-throughput sandwich enzyme-linked oligonucleotide assay for quantification and characterization of trastuzumab emtansine., PMID:39764977
Therapeutic drug monitoring of immunotherapies with novel Affimer-NanoBiT sensor construct., PMID:38249540
Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies., PMID:37419072
In vitro/in vivo degradation analysis of trastuzumab by combining specific capture on HER2 mimotope peptide modified material and LC-QTOF-MS., PMID:36038230
Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin., PMID:35930739
Improving Tumor Penetration of Antibodies and Antibody-Drug Conjugates: Taking Away the Barriers for Trojan Horses., PMID:34341064
Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model., PMID:30214017
ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer., PMID:29350568
Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis., PMID:29128290
LC-MS/MS strategies for therapeutic antibodies and investigation into the quantitative impact of antidrug-antibodies., PMID:27884074
Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases., PMID:26260958
Severe thrombocytopenia after trastuzumab retreatment: a case report., PMID:24093447
Off-rate screening for selection of high-affinity anti-drug antibodies., PMID:23906643
Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab., PMID:23731208
Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs., PMID:23143677
Cancer immunotherapy., PMID:21355777
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice., PMID:21294885
Anti-HER2 vaccines: new prospects for breast cancer therapy., PMID:20532501
Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer., PMID:20448672
The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry., PMID:19523916
A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy., PMID:19523913
The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum., PMID:19487098
[Anti-HER2 vaccines: The HER2 immunotargeting future?]., PMID:19481373
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma., PMID:19464994
Generation of Her-2/neu vaccine utilizing idiotypic network cascade., PMID:18059165
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy., PMID:17785568
Heterogeneity of recombinant antibodies: linking structure to function., PMID:16375256
[New antibodies in cancer treatment]., PMID:15500243
Monoclonal antibodies as effective therapeutic agents for solid tumors., PMID:15298722
Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice., PMID:15138490
Monoclonal antibodies in human cancer., PMID:14988743
Toward a breast cancer vaccine: work in progress., PMID:14569849
The therapeutic use of antibodies for malignancy., PMID:11499972
Antibody-targeted immunotherapy for treatment of malignancy., PMID:11160771
Monoclonal antibody therapy of cancer., PMID:10561017
An overview of monoclonal antibody therapy of cancer., PMID:10482193
For research use only. Not for human or drug use.
